依达拉奉对急性脑梗死患者血清S-100β蛋白和超敏C反应蛋白的影响  

Effects of edaravone on serum S-100β protein and high-sensitivity C-reactive protein of acute cerebral infarction

作　　者：李登星 

机构地区：[1]广西百色市人民医院神经内科,百色533000

出　　处：《中国实用神经疾病杂志》2009年第24期10-13,共4页Chinese Journal of Practical Nervous Diseases

摘　　要：目的研究依达拉奉对急性脑梗死（ACI）患者血清S-100β蛋白和超敏C反应蛋白（hs—CRP）水平的影响。方法选择我院2006-03-2008—10治疗的ACI患者106例，随机分为依达拉奉组56例，常规治疗组50例，常规治疗组给予常规治疗，依达拉奉组在此基础上给予依达拉奉，观察评价2组患者的血清S-100β蛋白浓度变化、血清hs—CRP浓度变化、神经功能改善及Barthel指数变化等。结果2组总体病情均明显好转，差异有统计学意义。依达拉奉组与常规治疗组的血清S-100β蛋白变化、血清hs-CRP变化、神经功能改善、Barthel指数变化等比较差异均有统计学意义（P〈0．05）。结论依达拉奉能明显降低ACI患者血清S-100β蛋白和hs—CRP水平，并有助于ACI患者的神经功能恢复。Objective To investigate the effects of edaravone on serum S-100β protein and high-sensitivity C-reactive protein （hs-CRP） of acute cerebral infarction. Methods A randomized double-blind study was designed to value effects of edaravone on acute cerebral infarction, with routine therapy as plaeeho-eontrol group. One hundred and six patients were chosen from Mar 2006 to Jun 2008, which were divided into two groups： edaravone group （56 cases） and control group （50 cases） . Serum levels of S-100β protein, serum levels of hs-CRP, improvement of neurological function and improvement of Barthel index were observed. Results There was better clinical outcome in the two groups, P〈0.01. There was a significant difference between two groups. In edaravone group, serum levels of S-100β protein, serum levels of hs-CRP, improvement of neurological function and improvement of Barthel index were elevated markedly compared with those in placebo-control group （P〈0.05）. Conclusion Edaravone can significantly decrease the level of S-100β protein and hs-CRP, and improve the neurological function of acute cerebral infarction.

关 键 词：急性脑梗死 依达拉奉 S-100Β蛋白 超敏C反应蛋白 

分 类 号：R743.33[医药卫生—神经病学与精神病学]